← Back to Search

Other

Low-Fat High-Fiber Diet for Crohn's Disease

N/A
Waitlist Available
Led By Maria T Abreu, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Documented diagnosed of Crohn's Disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a low-fat, high-fiber diet to help people with stomach problems and inflammation feel better.

Who is the study for?
This trial is for adults aged 18-70 with Crohn's Disease who have mild to moderate symptoms (sCDAI <400). They must not have used antibiotics or probiotics within the last two weeks and should be on stable doses of certain medications. Participants need to live with someone involved in their daily diet and can only be on low doses of steroids.
What is being tested?
The study tests a low-fat, high-fiber diet (LFD) designed to reduce gastrointestinal symptoms and inflammation in Crohn's patients. It includes Dyadic Psychological Support (DPS) and Diet Counseling to help participants adhere to the dietary changes.
What are the potential side effects?
While specific side effects are not listed for this dietary intervention, some individuals may experience changes in digestion or bowel habits as they adjust to the new diet.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with Crohn's Disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 36 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in fat intake
Rate of adherence to fat intake
Secondary study objectives
Change in clinical symptoms as assessed by Patient Reported Outcomes (PRO2).
Change in clinical symptoms as assessed by the Harvey Bradshaw Index (HBI)
Change in clinical symptoms as assessed by the Short Crohn's Disease Activity Index (sCDAI).
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Experimental CD Low Fat Diet (LFD) GroupExperimental Treatment1 Intervention
Participants will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks.
Group II: Experimental CD LFD + DPS GroupExperimental Treatment2 Interventions
Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
Group III: Crohn's Disease (CD) Control GroupActive Control1 Intervention
Participants will receive only the one time standard of care in-clinic diet counseling at visit 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dyadic Psychological Support (DPS)
2019
N/A
~300

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Crohn's Disease include dietary interventions, medications, and sometimes surgery. A low-fat, high-fiber diet aims to reduce inflammation and improve gut health by minimizing fat intake, which can exacerbate inflammation, and increasing fiber intake, which promotes healthy gut bacteria and bowel movements. This dietary approach can help manage symptoms and improve quality of life. Medications such as anti-inflammatory drugs, immunosuppressants, and biologics work by reducing inflammation and modulating the immune system to prevent flare-ups. These treatments are essential for Crohn's Disease patients as they help control symptoms, maintain remission, and prevent complications.

Find a Location

Who is running the clinical trial?

The Leona M. and Harry B. Helmsley Charitable TrustOTHER
65 Previous Clinical Trials
99,265 Total Patients Enrolled
University of MiamiLead Sponsor
949 Previous Clinical Trials
428,164 Total Patients Enrolled
Maria T Abreu, MDPrincipal InvestigatorUniversity of Miami
1 Previous Clinical Trials
51 Total Patients Enrolled

Media Library

CD LFD (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04213729 — N/A
Crohn's Disease Research Study Groups: Crohn's Disease (CD) Control Group, Experimental CD Low Fat Diet (LFD) Group, Experimental CD LFD + DPS Group
Crohn's Disease Clinical Trial 2023: CD LFD Highlights & Side Effects. Trial Name: NCT04213729 — N/A
CD LFD (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04213729 — N/A
~51 spots leftby Nov 2025